SecBot SecBot
6-K ·Filed Jun 11, 2026

GSK

GSK plc
NEUTRAL
Impact 1/10
Horizonimmediate Processed5mo ago SEC0001654954-26-005880
Notable filing: 6-K
Actionable Insight • Neutral

Routine share-reward plan transactions with no discretionary signal. Ignore for trading purposes; no follow-up required.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$52.86
T+0 close · Jun 11, 2026 · via day close
Latest settled
−5.62%
T+60 · $49.89
Vs SPY
−10.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 11 $52.86entry
  2. T+1 · 5mo ago +0.34%α −0.20% · $53.04
  3. T+5 · 5mo ago −1.34%α −1.78% · $52.15
  4. T+20 · 4mo ago −0.74%α −2.63% · $52.47
  5. T+60 · 2mo ago −5.62%α −10.01% · $49.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK filed a routine Form 6-K on June 11, 2026, disclosing eight PDMR transactions under the company's Share Reward Plan. Seven senior executives and one PCA acquired a total of 110 ordinary shares at £18.8393 per share on June 9, 2026. These are formulaic, pre-planned plan acquisitions, not discretionary open-market buys, with trivial aggregate value (~£2,070). The filing carries no material financial or strategic content.

Key Facts

  • Filed June 11, 2026, reporting transactions from June 9, 2026.
  • Eight PDMRs/PCA acquired shares: Lynn Baxter, Julie Brown (CFO), James Ford, David Redfern, Regis Simard, Philip Thomson, Deborah Waterhouse, Victoria Whyte, and Neil Falkingham (PCA of Lynn Baxter).
  • Type: acquisition under GSK's Share Reward Plan (partnership + matching shares).
  • Share price: £18.8393 per share; individual acquisitions range from 12 to 14 shares.
  • Total shares acquired: 110 ordinary shares; total consideration approximately £2,072 in GBP.
  • All transactions on the London Stock Exchange (XLON).
  • No open-market discretionary purchases; no sales reported.

Financial Impact

Trivial, aggregate value approximately £2,072 (110 shares × £18.8393), immaterial for a ~£104B market cap company.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-005880
Document: 0001654954-26-005880-index-headers.html0001654954-26-005880
Document: 0001654954-26-005880-index.html0001654954-26-005880
Document: 0001654954-26-005880.txt0001654954-26-005880

US Market Status

Market Closed · Opens Wed (10h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 11, 2026